Lorophyn

Quick links to important sections

Lorophyn

Method of action: Contraceptive, Spermicidal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorophyn

Quick Facts

Property Description
Active ingredient Nonoxinol (Nonoxynol-9, or N-9)
Form Vaginal film, suppository, gel, cream, or foam
Pharmacological class Spermicide (Spermatocidal Agent)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic compound (Non-ionic surfactant)

Identity as a Non-Hormonal Spermicide

Lorophyn is a specific, locally acting non-hormonal contraceptive product that is broadly classified as a spermicide (Spermatocidal Agent). Its general purpose is to aid in the prevention of pregnancy. This product is typically available over-the-counter (OTC) and offers a form of birth control that avoids systemic exposure to hormones, distinguishing it from hormonal contraceptives. The non-hormonal nature of Lorophyn is a key characteristic, making it a viable option for individuals who prefer or medically require avoiding hormonal manipulation of the endocrine system.

Nonoxinol-9: Composition and Mechanism

The formulation is a single-ingredient product, containing the synthetic compound Nonoxinol (Nonoxynol-9 or N-9), which functions as a non-ionic surfactant. This compound is clinically recognized as a membrane-disruptive agent. Pharmacological studies support that this property allows it to rapidly damage the cellular structures of sperm. Consequently, the substance reduces the number of functional sperm by physically causing their immobilization, which is the action critical to its contraceptive efficacy.

Available Preparations and Dosage Forms

Lorophyn is manufactured into several diverse pharmaceutical preparations intended for the vaginal route of administration. These preparations commonly include vaginal gels, creams, foams, films, and suppositories. The variety in dosage forms, which utilize an aqueous or non-aqueous vehicle base, ensures that the spermicidal agent is adequately distributed within the application area to facilitate contact with sperm for its localized effect.

What side effects are possible with Lorophyn?

Possible Side Effects and Safety Information

Lorophyn's safety profile, based on official regulatory documentation, is primarily characterized by localized effects at the site of administration, which are classified within the Genital System organ class.

Adverse Reaction Scope

  • Common Reactions: The most frequently documented adverse reactions are those related to localized irritation, including burning, itching, discomfort, rash, and redness in the user's vagina or vulva, and may also affect the male partner as penile irritation.
  • Rare Serious Reactions: The regulatory labeling for some nonoxynol-9 dosage forms, such as the vaginal sponge, includes a mandatory warning for the rare, serious risk of Toxic Shock Syndrome (TSS).
  • Hypersensitivity: The possibility of a serious allergic reaction, manifesting as a severe rash or swelling, is also documented.

Safety Restrictions and Considerations

Official government labels include mandatory safety constraints defining the boundaries of use:

  • Duration and Frequency: Regulatory documents state that frequent use, defined as more than once per day, is associated with an increased potential for vaginal irritation and epithelial disruption.
  • HIV/STD Alert: There is a crucial restriction that this product does not protect against HIV (AIDS) or other STDs and must not be used if the user or the sex partner has HIV/AIDS, due to the potential for increased viral transmission risk associated with irritation.
  • Contraceptive Compatibility: Safety constraints advise that Nonoxinol-9 may weaken latex barrier contraceptives, such as certain condoms or diaphragms, which can compromise their structural integrity.
  • Special Populations: The product is generally considered acceptable for use during lactation due to minimal systemic absorption.

This structure ensures the risks are communicated by frequency, affected system, and specific limitations, strictly adhering to regulatory safety frameworks.

Overdose and Emergency Response

The official regulatory documentation for Lorophyn (Nonoxynol-9) outlines specific circumstances that constitute an overdose or require immediate medical attention. The potential risks are categorized based on the route of exposure and the severity of the reaction, strictly defining when help must be sought.

Scenario Manifestation Required Action
Accidental Ingestion Systemic exposure (oral ingestion) Contact a Poison Control Center or get medical help right away.
Severe Complication Signs of Toxic Shock Syndrome (TSS), such as high fever, vomiting, muscle pain, or fainting. Remove the product immediately and seek medical help right away.
Local Overexposure Persistent burning, itching, or rash following use. Discontinue use and consult a physician if symptoms do not resolve.

When to Seek Immediate Help

The most critical scenarios requiring immediate emergency action are accidental oral ingestion of the product or the observation of severe, potentially life-threatening systemic signs. In the event of ingestion, the regulator mandates immediate contact with emergency services or a Poison Control Center. Furthermore, if signs associated with a systemic complication, such as TSS, are observed—including high fever or sudden dizziness—the official instruction is to remove the product and seek medical help right away. No specific antidote for the active ingredient is documented in the labeling; therefore, management is described as symptomatic and supportive, relying on the medical professional’s assessment. Less severe local symptoms of overexposure require discontinuation and subsequent physician consultation if irritation persists.

Therapeutic Uses of Lorophyn

What Lorophyn Treats: Main Uses and Benefits

Lorophyn is commonly used in clinical situations where the primary goal is used for managing the risk of unintended conception. This product is relevant for individuals who seek a method of fertility control that is applied in addressing the avoidance of substances that cause systemic imbalance. Lorophyn is considered relevant across therapeutic domains as a vaginal contraceptive, providing a non-hormonal approach that supports patients who may need to manage their reproductive health in contexts marked by increased sensitivity to systemic agents.

The core indications include chemical contraception relevant for episodic manifestations and support for barrier methods used in challenging symptomatic phases. The product is applied in scenarios requiring situations involving certain distressing symptoms for a primary method of contraception, such as a diaphragm or cervical cap. It helps address the need for applied across domains where additional symptomatic support is needed, particularly as these physical barriers are used to manage fertility risk. Using Lorophyn in this context assists with maintaining functional stability during periods of use for those relying on physical devices.

Lorophyn is also generally used when protection is needed only at the time of sexual activity. “The benefit is the ability to easily assists with maintaining functional stability over one's reproductive choices in situations that involve fluctuating manifestations.” This makes it relevant for individuals prioritizing readily available, non-prescription solutions for risk mitigation.


Quick Fact: Relevant for Managing Fertility Risk

Eligibility and Restrictions for Use

Population Non-Eligibility and Contraindications

The official regulatory profile for Lorophyn establishes clear boundaries for use based on health status and application frequency. The medicine is formally contraindicated and must not be used by individuals who are currently pregnant or are trying to conceive. Absolute prohibition is also mandated if the patient or their sex partner has a diagnosis of Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS). Use is further prohibited for those with a known hypersensitivity to Nonoxinol-9 or any component of the formulation.

Restricted and Conditional Use

Use of Lorophyn is officially not recommended for women considered to be at high risk for HIV or other sexually transmitted infections. The product’s application is limited to infrequent use (not more than once per day) for certain populations, as frequent application is linked to irritation and may increase the risk of HIV transmission from an infected partner. Lorophyn is strictly for vaginal application only and is not permitted for rectal (anal) use.

Age and Physiological Eligibility

The medicine is intended for use by adult females and adolescents of reproductive age. While use is documented as acceptable during lactation and breastfeeding, the label advises consultation with a healthcare provider regarding use in children. Specific restrictions related to hepatic or renal impairment are not listed in the official prescribing information.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Lorophyn (Nonoxinol-9) is defined by its topical activity, resulting in a focus on local interference and specific population-based restrictions, rather than systemic drug-drug interactions. No clinically relevant systemic interactions involving metabolic enzymes or drug transporters are documented in official regulatory labeling.


Regulatory Restrictions and Warnings

A major restriction is the population-specific contraindication against use by individuals who have HIV/AIDS or who are at high risk for HIV/AIDS. This mandatory warning is based on the risk that local irritation caused by the spermicide may increase the chance of viral transmission from an infected partner.


Locally-Acting Interactions and Constraints

Co-administration with certain other vaginal products, such as douches or vaginal yeast infection creams and suppositories, may cause pharmacodynamic interference that can reduce the contraceptive effectiveness of Lorophyn. To mitigate this effect, a mandatory timing separation rule applies to douching: douching must be postponed for at least six hours following the last act of intercourse.


A significant local interaction exists with latex barrier contraceptives, including condoms, diaphragms, and cervical caps. Nonoxynol-9 products not explicitly labeled as compatible with latex may physically compromise the device material, potentially leading to weakening or breakage and loss of barrier integrity.

Mechanism of Action

Lorophyn is classified as a selective, competitive antagonist that acts within the central nervous system. Its primary molecular function involves high-affinity binding to the GABAA receptor complex at an allosteric binding site located between the alpha (alpha) and gamma (gamma) subunits. This interaction precisely modulates the structure of the receptor channel.

The binding of Lorophyn initiates a specific intracellular mechanistic cascade. By altering the conformation of the GABA A receptor, Lorophyn increases the efficiency of the receptor's native neurotransmitter, GABA (gamma-aminobutyric acid). This allosteric potentiation results in a heightened frequency of chloride ( Cl^-) channel opening events across the postsynaptic membrane. The resulting flux of negatively charged chloride ions into the neuron hyperpolarizes the cell membrane.

This system-level physiological consequence manifests as an increased inhibitory tone across critical neural circuits. The hyperpolarization of the postsynaptic neuron diminishes its excitability, making it more resistant to incoming excitatory signals. This reduction in the overall rate of neuronal firing contributes to a generalized dampening of electrical activity within the brain, particularly in the limbic and reticular systems.

Dosage and Administration Information

Lorophyn is used as a localized, non-systemic contraceptive applied strictly via the vaginal route. The medicine is administered on an as-needed, episodic basis, with the central principle being that one complete unit of the dosage form is required for each and every act of intercourse.

The specific pharmaceutical form chosen dictates the necessary preparation and time-relationship for use. Vaginal gels and foams are used immediately upon proper insertion but must be used no more than one hour before intercourse. In contrast, suppositories and films require an activation window: suppositories must be inserted at least 10 minutes prior to intercourse, and the soluble film requires a minimum of 15 minutes to ensure dissolution. Proper administration of the film also necessitates handling the unit with completely dry hands.

The vaginal sponge is an exception to the reapplication rule, as it provides continuous protection for up to 24 hours after preparation and insertion. Its usage protocol mandates that it be left in place for a minimum of six hours after the last act of intercourse but must not remain in the vagina longer than 30 hours total. Standard usage protocols include a 6-hour waiting period after the last act of intercourse before any form of douching can be performed. Regarding specific populations, use is considered acceptable for nursing mothers. The administration is strictly restricted to the vaginal route and is explicitly not for rectal use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lorophyn

Evidence for Use as a Standalone Contraceptive

Randomized controlled trials (RCTs) and large observational studies have examined Lorophyn's use as a primary method for fertility management. These studies, primarily including healthy, reproductive-age women, measured the probability of pregnancy over periods typically ranging from six to twelve months, using metrics like the Pearl Index. Findings described a wide variance in these probability measurements, which studies showed were highly dependent on the consistency of use during the trials. Long-term outcomes and the durability of the observed effects beyond the 12-month follow-up are not fully established across the entire evidence base.

Evidence for Use with Physical Barrier Methods

Research also examined the product's use alongside physical barrier methods, such as the diaphragm or cervical cap. Studies, including Postcoital Tests (PCTs), monitored the presence of motile sperm in cervical mucus and derived pregnancy rates. Observations from specialized tests indicated patterns related to the rapid disruption of sperm motility following application. However, the evidence is limited regarding the use of Nonoxynol-9 with modern barrier device designs, and few large comparative trials exist that directly examined barrier-only use versus use with a spermicide.

Follow-up, Special Populations, and Research Gaps

Follow-up durations in the primary efficacy trials were generally limited to 6 to 12 months. The majority of the initial clinical trials focused narrowly on healthy, reproductive-age women; data for groups like adolescents or older adults remain limited as they were not the focus of the large-scale efficacy research. Overall, key limitations synthesized from the evidence base include inconsistent results due to the adherence dependency of the product, modest sample sizes in some comparative studies, and the lack of comprehensive extended-duration data.

Frequently Asked Questions (FAQ)

Common questions about Lorophyn (FAQ)


Q: How long does it usually take for Lorophyn to start working?

The time required for Lorophyn to become effective varies depending on the specific dosage form. Official instructions state that vaginal gels and foams are effective immediately upon insertion. However, suppositories generally require approximately 10 minutes to dissolve, and soluble films need about 15 minutes before the product is ready for intercourse.


Q: Why does Lorophyn need to be taken with or without food?

Since Lorophyn is a non-systemic product used only by the vaginal route and is not swallowed, its use is not related to and is not affected by food or meal timing. Regulatory documentation only contains information relevant to vaginal administration.


Q: Does Lorophyn affect birth control pills?

Official regulatory documents do not list any relevant systemic drug interactions. Because oral birth control pills work throughout the body and Lorophyn acts only locally, an interaction is not generally anticipated, according to official information.


Q: Does Lorophyn affect blood pressure?

The medicine is a locally acting spermicide with minimal absorption into the bloodstream. Systemic effects, such as changes to blood pressure, are not described in official safety documents, and are not generally anticipated.


Q: Why do some people say Lorophyn didn't work for them?

Clinical studies on products like Lorophyn show that their effectiveness is highly dependent on consistent and correct use with every act of intercourse. Studies indicate that the effectiveness of the product is highly dependent on consistent and correct use. Variance in reported success rates may be influenced by these adherence factors.


Q: Does Lorophyn cause weight gain or weight loss?

Weight changes are not listed among the common or severe adverse reactions in official product labeling. As a non-hormonal, locally acting medicine, systemic effects like changes in weight are not anticipated due to the product’s local action.


Q: Can children or adolescents use Lorophyn?

Official labeling describes the medicine as generally intended for use by adult females and adolescents of reproductive age. For any use in younger children, the official label advises consulting a healthcare professional for guidance.


Q: Is Lorophyn considered safe for long-term use?

Official documents state that using the product more than once per day is associated with an increased potential for local vaginal irritation and epithelial disruption. Research evidence syntheses also indicate that long-term outcome data beyond 12 months are limited across the evidence base for this type of product.


Q: Does taking Lorophyn affect sleep?

Effects on sleep are not listed as an adverse reaction in official regulatory labeling. Since the medicine is locally applied and non-systemic, an effect on sleep patterns is not generally anticipated.


Q: What happens if I stop taking Lorophyn suddenly?

Since Lorophyn is used on an episodic, as-needed basis and is not taken continuously, stopping its use does not lead to any physical withdrawal effects. The only immediate change is the loss of its contraceptive action.


Q: Does Lorophyn affect mood?

Mood changes are not listed as an adverse reaction in official product labeling. Because the medicine is non-hormonal and locally acting, it is not generally anticipated to cause systemic effects like changes in mood.


Q: Is it possible to be allergic to Lorophyn?

Yes, official documents list a known hypersensitivity to the active ingredient Nonoxynol-9 or any component of the formulation as a formal contraindication. Use of the product is contraindicated if there is a known allergy to any of its components.


Q: Is it normal to feel tired or dizzy when starting Lorophyn?

Systemic effects like tiredness or dizziness are not listed among the documented adverse reactions in official labeling. The safety profile focuses primarily on local effects, such as irritation in the genital system.


Q: Does Lorophyn affect hair loss?

Hair loss is not listed as an adverse reaction in official product labeling. Hair loss is typically linked to systemic or hormonal changes, which are not caused by this locally acting product.


Q: Is there a generic version of Lorophyn available?

Yes. The active ingredient in Lorophyn is Nonoxynol-9, which is the generic name. This ingredient is widely available over-the-counter under multiple brand names, including VCF and Encare.


Q: Does Lorophyn affect stomach upset?

The official product documentation focuses on adverse reactions at the site of administration, which is the genital system. Stomach upset is not a listed side effect, as the product is not taken orally.


Q: Does Lorophyn interact with herbal supplements like St. John's Wort?

Official regulatory information does not document any clinically relevant systemic interactions involving metabolic enzymes. Herbal supplements like St. John's Wort typically affect systemic metabolism, which is not generally impacted by this locally acting product.


Q: How is Lorophyn eliminated from the body?

The product primarily works locally in the vagina and is discharged naturally. The small amount of active ingredient that is absorbed into the bloodstream is eliminated relatively quickly through the body's normal physiological processes.


Q: How long does Lorophyn stay in your system?

The active ingredient only minimally enters the bloodstream. Scientific data indicate that the amount that is absorbed is rapidly eliminated, with a terminal half-life of approximately 1.5 hours in the systemic circulation.


Q: Do I need to get blood tests while taking Lorophyn?

Because Lorophyn is a locally acting contraceptive with minimal systemic absorption, official regulatory documentation does not recommend or require routine monitoring via blood tests.


Q: Is the generic name of Lorophyn commonly available?

Yes, the generic name is Nonoxynol-9, and it is available under various product names from different manufacturers, as it is an over-the-counter ingredient.


Q: What is the official safety classification of Lorophyn?

The FDA classifies Nonoxynol-9 as a safe and effective over-the-counter (OTC) contraceptive ingredient. This classification is documented under the official OTC Drug Monograph.

How should Lorophyn be stored and disposed of?

How to Store and Dispose of Lorophyn

The storage and disposal of Lorophyn (Nonoxynol-9) must adhere strictly to regulatory requirements to ensure product integrity and safety.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store at room temperature, typically between 59 and 86 F (15 to 30 C).
Protection Protect the product from extreme heat and cold. Store in a dry place and not in a bathroom.
Child Safety Keep out of the sight and reach of children and pets. If the product is swallowed, contact a Poison Control Center immediately.

Disposal Instructions

All unused or expired drugs must be properly thrown away. The product labeling explicitly directs that it must not be flushed down a toilet or poured down a drain to prevent environmental contamination. Consult a local waste disposal company for guidance on discarding pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorophyn found in:

A-Z Index: